10 slides from PDS Biotechnology's conference presentation, Sep 19, 2023
Slide 1: Influenza pre-immune ferrets vaccinated with computationally optimized recombinant HA proteins
Influenza pre-immune ferrets vaccinated with computationally optimized recombinant HA proteins generate sero-protective antibody responses against H1N1 and H3N2 viruses from the last decade Dr. James Allen Cleveland Clinic Florida Research and Innovation Center Port Saint Lucie, FL, USA September 19
Slide 2: COBRA Approach for Designing Broadly Reactive Vaccines
COBRA Approach for Designing Broadly Reactive Vaccines • In-silico layered consensus building approach • Utilizes HA sequence data from flu surveillance databases (GISAID, GenBank) • Natural viral evolution dictates antigen design • Capable of eliciting potent, broadly reactive HA-specific antibody
Slide 3: Overview of different COBRA vaccine delivery platforms
Overview of different COBRA vaccine delivery platforms HA and NA recombinant DNA vaccination mRNA LNP proteins Nano, Micro, & Virus-like particles Inactivated/Split (VLP) vaccine Recombinant ChAd3 AAV - Live or Attenuated Viruses Vectored Self-amplifying mRNA
Slide 4: Infectimune Adjuvant
Infectimune® Adjuvant • Infectimune® (R-enantiomer of DOTAP) • Cationic lipid nanoparticle adjuvant • Quaternary ammonium head with two 18 carbon length unsaturated fatty acid (acyl) chains • Binds to surface of DCs and is endocytosed via a clathrin-mediated mechanism • Efficient at transporting pro
Slide 5: Pre-immune Ferret Model
Pre-immune Ferret Model • Mimic human response to vaccination by first infecting ferrets with influenza viruses - H1N1 (A/Singapore/6/1986) - H3N2 (A/Panama/2007/1999)
Slide 6: H1N1 HAI Response
H1N1 HAI Response • H1/H3 Pre-immune ferrets vaccinated 2x with Y2/NG2 rHA (15ug) + Infectimune® or wild-type rHA + Infectimune® Y2 + NG2 Mich/15 + Sing/16 14 14 12 12 Log 2 HAI Titer Log 2 HAI Titer 10 10 8 8 1:80 1:80 6 6 1:40 1:40 4 4 2 2 9 B 5 ua 8 9 B 5 ua 8 9 19 9 19 /0 1 /1 /0 1 /1 /1 /1 h/ c
Slide 7: H3N2 HAI Response
H3N2 HAI Response • H1/H3 Pre-immune ferrets vaccinated 2x with Y2/NG2 rHA (15ug) + Infectimune® or wild-type rHA + Infectimune® Y2 + NG2 Mich/15 + Sing/16 14 14 12 12 Log 2 HAI Titer Log 2 HAI Titer 10 10 8 8 1:80 1:80 6 6 1:40 1:40 4 4 2 2 3 Si 4 K 6 Sw 1 7 7 9 9 20 3 Si 4 K 6 Sw 1 7 7 9 9 20 /1 /
Slide 8: H1N1 Infection Results
H1N1 Infection Results A/Victoria/2570/2019 H1N1 D3 Nasal Wash Viral Titers 1e6 PFU/mL 105 120 104 % Original Body Weight Y2 + NG2 110 PFU/mL 103 Mich/15 + Sing/16 Mock 102 100 101 LOD 90 100 80 Si 2 6 k G /1 oc N ng M + 0 1 2 3 4 5 6 7 8 D9 D0 D1 D2 D3 14 1 D D D D D D D D D D 1 1 1 Y2 + 15 Days Po
Slide 9: Conclusions
Conclusions • COBRA rHA vaccines adjuvanted with Infectimune® capable of eliciting protective HAI antibody responses in pre-immune ferrets across panels of viruses from the last decade - Also elicit HAI reactive antibodies against future drifted viral isolates from 2019-2020 - Prevent weight loss an
Slide 10: Acknowledgements
Acknowledgements • Dr. Ted Ross • Jessica Medina • Hua Shi • Matthew Thomas • Dr. Xiaojian Zhang • Julia Aguirre • Dr. Jerry Woodward • Zachary McGuire • Dr. Siva Gandhapudi • Spencer Pierce • Michael Carlock • This project has been funded by the National Institute of Allergy and Infectious Diseases